• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Emergent BioSolutions Inc. Common Stock (NY:EBS)

    5.925 -0.325 (-5.20%)
    Delayed Quote Updated: 3:58 PM EST, Nov 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Emergent BioSolutions Inc. Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Emergent Biosolutions Reports Third Quarter 2026 Financial Results
    From Emergent BioSolutions Inc.
    Via Business Wire
    News headline image
    Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
    From Emergent BioSolutions Inc.
    Via Business Wire
    News headline image
    Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
    From Emergent BioSolutions Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Reports Second Quarter 2026 Financial Results
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
    Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources 
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions to Participate in Upcoming Investor Conferences
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Reports First Quarter 2026 Financial Results
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
    From Emergent BioSolutions
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.